Ratchapol Siriprapaphan

Ratchapol Siriprapaphan

Auto-generated profile, based on publicly available information

Ratchapol Siriprapaphan

Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Samut Prakan, Thailand

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2025 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
PNPrachawanee Nuchpramool
Prachawanee Nuchpramool
CTChatsaran Thanapongpibul
Chatsaran Thanapongpibul
RSRatchapol Siriprapaphan
Ratchapol Siriprapaphan
NKNarathorn Kulthamrongsri
Narathorn Kulthamrongsri
Leuprolide acetate is commonly used to reduce the size of myomas before surgery. Initially, it stimulates pituitary gonadotropin secretion, followed by sustained suppression of gonadal function. However, the impact on pregnancy outcomes from inadvertent exposure remains unclear. This case involves a woman in her 30s, multiparous, with a 20-week-sized leiomyoma, who received two doses of 3.75 mg subcutaneous leuprolide acetate, 15 days after menstruation, 4 weeks apart. An ultrasound, conducted 2 weeks after the last dose, accidentally revealed a viable intrauterine pregnancy at 8+6 weeks gestation. Her pregnancy progressed without complications, culminating in a term caesarean delivery without fetal anomalies. She opted for a total hysterectomy with bilateral salpingectomy 6 months later. Despite unclear teratogenic effects, evidence suggests that leuprolide acetate does not significantly impact pregnancy outcomes.